Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Dec 6, 2025 12:58 AM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
A Fresh Look (and New Features) for the Acton PowerBlog
We’ve launched a redesigned Acton PowerBlog but there’s more to it than just a visual update. You’ll find the following enhancements: A simpler look that seeks to better emphasize important features of the blogConvenient tab navigation on the right for frequently used itemsIncreased real estate for blog posts like the one you’re readingIncreased emphasis on social media including:New links near the top right and bottom of the page to Acton’s key social pagesA live Facebook page stream on the right...
Samuel Gregg: Debt, Finance, and Catholics
In Crisis Magazine, Acton Research Director Samuel Gregg has a new article that looks at how Catholics reflect on a wide range of financial questions ranging from the federal government’s fiscal woes to consumer debt to a fragile banking system. Today one looks in vain for Catholic thinkers studying our debt and deficit problems from standpoints equally well-informed by economics and sound Catholic moral reflection. We don’t, for instance, hear many Catholic voices speaking publically about the moral virtues essential...
Economic Recession and Charitable Giving
I’ve written a fair bit over recent months about trends in charitable giving and Christian tithing. One the latter point, I touched on the importance of tithing in my latest “On the Square” feature at the First Things site. I’m looking forward to getting a look at Douglas LeBlanc’s book, Tithing: Test Me in This. We are seeing right now just how critical faithful charity can be in the midst of disaster. The Barna Group recently released a major new...
The West and the Rest
Over at the Comment site, I review Dambisa Moyo’s How the West was Lost: Fifty Years of Economic Folly—and the Stark Choices Ahead. In “War of the Worldviews,” I note that the strongest elements of Moyo’s work are related to her analysis of the causes and the trends of global economic power. “Faced with bined might of the Rest,” writes Moyo, “the West is forced to grapple with a relentless onslaught of challengers from all corners of the globe. And...
Out of the Whirlwind: God’s Love and Christian Charity
mentary is about the recovery efforts in the aftermath of the tornadoes that struck the South in late April. The focus of this piece is primarily what is going on in Alabama, but it is true for the entire region that was affected. I’d like to thank Jeff Bell of Tuscaloosa for lending his time to talk with me about his experiences. There were so many inspirational anecdotes and stories he offered. I only wish there was room to include...
Meaningful Work and Enterprise Culture in China
To conclude the Acton Institute’s May 18 Rome conference, Family-Enterprise, Market Economies, and Poverty: The Asian Transformation, panelist Fr. Bernardo Cervellera reminded the audience of a fundamental principle to sustain the long term growth of any free economy: spiritually meaningful work. Fr. Bernardo Cervellera, the outspoken missionary of the Pontifical Institute of Foreign Missions (PIME) and editorial director of AsiaNews (a leading Catholic news agency) recounted some controversial stories from his nearly twenty years experience in China as a professor...
St. Clement of Alexandria on the Value of Wealth
I wrote several blogs last week about the value and importance of the Church Fathers. One of the early Greek Fathers was Clement of Alexandria, born in Athens around A.D. 150. His parents were pagans. He was converted to faith in Christ and began to travel widely searching for faithful Christian teachers. He attended the famous School of Theology in Alexandria, founded by Pantaenus in A.D. 180. After he settled there he became the director of the school, thus Clement...
Fair Trade: Are Good Intentions Enough?
Tomorrow evening economist Victor Claar will be leading an Acton on Tap where he will talk about fair trade. As a Christian and an economist, Claar brings a unique perspective to the discussion. He will be asking a number of key questions including: Is fair trade truly the best way to help the poor, and, if not, then what can we do instead? The blog, Common Sense Concept, recently reviewed Claar’s new book, Fair Trade? Its Prospects as a Poverty...
Will I need a CFL Bulb Waiver?
Incandescent light bulbs are months away from being banned because they do not meet the efficiency requirements passed by Congress in 2007 that take effect starting 2012; however, before the ban takes place there may be a need to further evaluate the safety and benefits of CFL light bulbs. New research has some concerned that CFL bulbs contain cancer causing chemicals: …German scientists claimed that several carcinogenic chemicals and toxins were released when the pact fluorescent lamps (CFLs) were switched...
Audio: The Impact of Religion on Economic Development
Last week, the Acton Institute held a conference in Rome examining the rise of Asian Economies. One of the keynote speakers was Thomas Hong-Soon Han, the Ambassador of the Republic of Korea to the Holy See. Vatican Radio spoke with him about the topic of the conference; you can listen to the interview using the audio player below: [audio: ...
Related Classification
Copyright 2023-2025 - www.mreligion.com All Rights Reserved